local_hospital

Centre Hospitalier Du Puy

Address
lock Available on a paid plan

Kidney and Cardiovascular Research

At Centre Hospitalier Du Puy, clinical research in nephrology and cardiovascular diseases focuses on conditions such as immunoglobulin A nephropathy, chronic kidney disease, acute kidney injury, and broader heart and blood vessel disease. These studies are designed to test new treatment options, slow kidney function loss, and reduce major cardiovascular events in people at elevated risk.

  • Immunoglobulin A nephropathy and proteinuria reduction
  • Chronic kidney disease with high blood pressure and cardiovascular risk
  • Acute kidney injury recovery and long-term outcomes
  • Cardiovascular disease prevention in advanced kidney disease

Much of this work explores whether newer therapies can better protect kidney function while also improving overall cardiovascular health.

Autoimmune and Inflammatory Diseases

The site also supports trials in immune system diseases, especially rheumatoid arthritis. Research here is aimed at finding more effective ways to control persistent inflammation and improve symptoms in patients whose disease has not responded well to standard care.

  • Rheumatoid arthritis with refractory disease
  • Immune system processes involved in treatment response
  • Combination treatment strategies for better disease control

These studies help clarify whether newer immune-targeted approaches can offer stronger and more lasting relief.

Oncology and Cancer Care

Clinical trials in neoplasms at this hospital include research in breast cancer, colon carcinoma, and follicular lymphoma. The main goals are to improve treatment effectiveness, refine cancer management after diagnosis, and support better outcomes for patients with advanced or recurrent disease.

  • Estrogen receptor-positive, HER2-negative breast cancer
  • Colon cancer and tumor DNA-guided treatment decisions
  • Follicular lymphoma and combined therapy approaches
  • Venous thromboembolism in patients with cancer

These studies reflect a strong interest in both direct cancer treatment and the prevention of complications that can affect people living with cancer.

Blood Clotting and Vascular Prevention

Another important area of research involves hemic and lymphatic diseases and vascular medicine, including studies of venous thromboembolism, stroke, and other major vascular events. The purpose is to evaluate whether new blood-thinning strategies can better prevent recurrence and reduce serious complications.

  • Venous thromboembolism in cancer-associated conditions
  • Stroke and recurrent vascular event prevention
  • Myocardial infarction and related cardiovascular outcomes

At Centre Hospitalier Du Puy, this research supports safer and more effective prevention strategies for patients at high risk of clotting events.

Infectious Disease and Vaccine Studies

Within the infectiology department, the site is also involved in research on respiratory tract diseases and infection prevention, including work related to pneumococcal infection. These trials are focused on strengthening immune protection and assessing how well vaccination performs in people with increased infection risk.

  • Pneumococcal vaccine response in high-risk adults
  • Immune response during and after febrile illness
  • Prevention of invasive bacterial infection

This area of research helps improve practical vaccination strategies for patients who may be more vulnerable to serious infections.

Site Overview

assignment
18
connected trials
corporate_fare
12
sponsors
science
65
IMPs

Activity Indicator

Last 6 months

1
Trials started
New activity detected vs previous period.
0
Trials started 6–12 months ago
18
Total trials linked
Highly Active
trending_upGrowing+100%
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 3 of 10 therapeutic areas and 15 of 65 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 64 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
11
Sponsors (total)
12
Active sponsors
8

Sponsor Network

Top 8 by active trials.

lock +7 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +4 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 978 other sites in France

description
Trial volume
18
Outperforms 79% of sites
public
Therapeutic diversity
10areas
Outperforms 84% of sites
groups
Sponsor diversity
12sponsors
Outperforms 79% of sites

Therapeutic Area Benchmark — France

Select a therapeutic area to compare against other sites in France.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: France

Market Share

Country: France

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Centre Hospitalier Du Puy

lock Showing 1 of 18 trials — the rest is available on a paid plan.

IMP list

lock Showing 1 of 65 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Fluorouracil3Unknown2024-06-072026-05-07

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.